Efficacy and safety of long-term infliximab therapy in moderate to severe psoriasis and psoriatic arthritis

Giornale Italiano di Dermatologia e Venereologia

Volumn 141, Issue 1, 2006, Pages 73-78

  Bianchi, L ^a   Giunta, A ^a   Papoutsaki, M ^a   Costanzo, A ^a   Chimenti, S ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Biologic therapy; Monoclonal antibodies; Tumor necrosis factor alpha

Indexed keywords

CYCLOSPORIN A; ETRETIN; ETRETINATE; INFLIXIMAB; METHOTREXATE; STEROID;

ADULT; AGED; ARTHROPATHY; ARTICLE; CHRONIC INFLAMMATION; DELAYED HYPERSENSITIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; EVALUATION; FEMALE; FOLLICULITIS; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; HYPERTENSION; INCIDENCE; INFECTION; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MALE; PAIN ASSESSMENT; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RATING SCALE; TREATMENT OUTCOME;

EID: 33645118579     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Capon F, Semprini S, Chimenti S, Fabrizi G, Zambruno G, Murgia S et al. Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J Invest Dermatol 2001;116:728-30.
2. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999;20:40-6.
3. Gottlieb AB. Immunopathogenesis of psoriasis. Arch Dermatol 1997;133:781-2.
4. Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol 1992;126:1-9.
5. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-7.
6. Greaves MW. Treatment of psoriasis. N Engl J Med 1995;322:581-8.
7. Gottlieb AB, Bos JD. Short analytical review. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 2002;105:105-16.
8. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M et al. Construction and initial characterization of a mouse-human chimeric anti TNF anti-body. Mol Immunol 1993;30:1443-53.
9. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001;357:1842-7.
10. Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int 2002;22: 227-32.
11. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002;46:886-91.
12. Kirby B, Marsland AM, Carmichael AJ, Griffiths CE. Successful treatment of severe recalcitrant psoriasis with combination of infliximab and methotrexate. Clin Exp Dermatol 2001;26:27-9.
13. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor (TNF-) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000;42: 829-30.
14. Ramey DR, Fries JF, Singh G. Health Assessment Questionnaire 1995 - Status and Review. In: Spilker B., editor. Quality of Life and Pharmacol Economics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven Pub. 1996. p. 227-37.
15. Fries JF, Spitz P, Kraines G, Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
16. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumor necrosis factor-alpha biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-51.
17. Barnes PJ, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory disease. N Engl J Med 1997;336: 1066-72.
18. Bonifati C, Carducci M, Cordiali Fei P, Trento E, Sacerdoti G, Fazio M et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients: relationship with disease severity. Clin Exp Dermatol 1994;19:383-87.
19. Mussi A, Bonifati C, Carducci M, D'Agosto G, Pimpinelli F, D'Urso D et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997;11:115-8.
20. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999;13:16-22.
21. Baecklund E, Sundstrom C, Ekbom A, Catrina AI, Biberfeld P, Feltelius N et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003;48:1543-50.
22. MacDermott RP, Stenson WF. Alterations of the immune system in ulcerative colitis and Crohn's disease. Adv Immunol 1988;42:285-328.
23. Greenstein AJ, Gennuso R, Sachar DB, Heinemann T, Smith H, Janowitz HD et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985;56:2914-21.